<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04838639</url>
  </required_header>
  <id_info>
    <org_study_id>360-101</org_study_id>
    <nct_id>NCT04838639</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 in Healthy and Obese Adult Subjects</brief_title>
  <official_title>A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of NO-13065 When Administered Orally to Healthy and Obese Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Otsuka Pharmaceutical Factory, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celerion</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Otsuka Pharmaceutical Factory, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical trial is the first-in-human study of NO-13065. The purpose of this phase 1&#xD;
      study is to assess the safety and tolerability of single and multiple ascending oral doses&#xD;
      and food effect of NO-13065 in healthy and obese adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 14, 2021</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number and severity of treatment emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 35 days</time_frame>
    <description>To assess the safety and tolerability of single and multiple ascending oral doses of NO-13065 in healthy, overweight, and obese adult subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>Up to 35 days</time_frame>
    <description>To assess Cmax of single and multiple ascending oral doses of NO-13065 in healthy, overweight, and obese adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration-time curve (AUC)</measure>
    <time_frame>Up to 35 days</time_frame>
    <description>To assess AUC of single and multiple ascending oral doses of NO-13065 in healthy, overweight, and obese adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax (Tmax)</measure>
    <time_frame>Up to 35 days</time_frame>
    <description>To assess Tmax of single and multiple ascending oral doses of NO-13065 in healthy, overweight, and obese adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent first-order terminal elimination half-life (t ½)</measure>
    <time_frame>Up to 35 days</time_frame>
    <description>To assess t ½ of single and multiple ascending oral doses of NO-13065 in healthy, overweight, and obese adult subjects.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between QTc and NO-13065 plasma concentrations</measure>
    <time_frame>Up to 29 days</time_frame>
    <description>To explore the correlation between changes in QTc interval (msec) and NO-13065 plasma concentrations, appropriate correction method for QTc interval calculation such as QTcF will used for analysis.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>NO-13065, oral tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo matched to NO-13065, oral tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NO-13065</intervention_name>
    <description>Single ascending doses of NO-13065 in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.&#xD;
Single ascending dose of NO-13065 with food effect arm. Multiple ascending doses of NO-13065 for 10 or up to 28 days in separate cohorts of subjects; each cohort consists of 6 subjects treated with NO-13065.</description>
    <arm_group_label>NO-13065, oral tablet</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Two subjects per cohort will take a matched placebo.</description>
    <arm_group_label>Placebo matched to NO-13065, oral tablet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Healthy adult male and/or female (non-childbearing potential only), 19 to 55 years of&#xD;
             age&#xD;
&#xD;
          2. Continuous non-smoker&#xD;
&#xD;
          3. Medically healthy with no clinically significant medical history, physical&#xD;
             examination, laboratory profiles, vital signs or safety ECGs.&#xD;
&#xD;
          4. Women of non-childbearing potential only&#xD;
&#xD;
          5. Able to understand and sign a written informed consent form prior to initiation of&#xD;
             study procedures.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject is mentally or legally incapacitated or has significant emotional problems&#xD;
&#xD;
          2. History or presence of clinically significant medical or psychiatric condition or&#xD;
             disease&#xD;
&#xD;
          3. History or presence : Familial hyperlipidemia, Diabetes, Bleeding disorder(s),&#xD;
             including relevant familial history, Thromboembolic disease, Bleeding in the&#xD;
             gastrointestinal tract or CNS, Hepatobillary disease, Gilbert's syndrome&#xD;
&#xD;
          4. History or presence of alcohol or drug abuse.&#xD;
&#xD;
          5. Has liver function test(s) including ALT, AST, GGT, and/or ALP or total bilirubin that&#xD;
             are &gt; ULN at screening or check-in.&#xD;
&#xD;
          6. Positive urine drug or alcohol results.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Koushi Iwata</last_name>
    <role>Study Chair</role>
    <affiliation>Otsuka Pharmaceutical Factory, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Koushi Iwata, MSc</last_name>
    <phone>+81-88-685-1151</phone>
    <email>OPF-ClinicalTrials@otsuka.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Celerion</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 30, 2021</study_first_submitted>
  <study_first_submitted_qc>April 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 9, 2021</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

